Physician profile
Robert B Mann
NPI 1548371347
$2,409.17
in general payments reported to CMS, 2019-2025
23 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2020: $343 · 2021: $738 · 2022: $478 · 2023: $245 · 2024: $190 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $559.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $415.15 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Pfizer INC. | $389.83 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $365.82 | 2020-2025 | Jardiance |
| Lilly USA, LLC | $152.06 | 2022-2024 | Mounjaro |
| Amarin Pharma, INC. | $144.07 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $103.42 | 2020-2021 | |
| Esperion Therapeutics, INC. | $96.10 | 2021-2025 | Nexletol |
| Abbvie INC. | $92.84 | 2021-2022 | |
| Novo Nordisk INC | $82.52 | 2019-2025 | Ozempic |
| Glaxosmithkline, LLC. | $81.83 | 2022-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $76.97 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $75.40 | 2019 | |
| Amgen INC. | $66.90 | 2019-2024 | Repatha, Otezla |
| Mylan Specialty L.P. | $61.44 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $61.32 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $28.85 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.53 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $18.63 | 2025 | Rexulti |
| Shield Therapeutics INC | $17.93 | 2023 | Accrufer |
| Bayer Healthcare Pharmaceuticals INC. | $15.16 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $14.05 | 2025 | Farxiga |
| Sanofi Pasteur INC. | $11.32 | 2019 | |
| Allergan, INC. | $11.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.